Wealth Architects LLC Has $212,000 Stock Holdings in Stryker Co. (NYSE:SYK)

Wealth Architects LLC trimmed its holdings in shares of Stryker Co. (NYSE:SYK) by 12.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 590 shares of the medical technology company’s stock after selling 82 shares during the period. Wealth Architects LLC’s holdings in Stryker were worth $212,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of SYK. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the 4th quarter worth about $25,000. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Rakuten Securities Inc. boosted its stake in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after buying an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker during the 4th quarter worth about $30,000. Finally, BankPlus Trust Department acquired a new position in shares of Stryker during the 4th quarter worth about $33,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE:SYK opened at $373.65 on Tuesday. The company’s 50 day moving average price is $383.29 and its two-hundred day moving average price is $373.71. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The firm has a market cap of $142.58 billion, a PE ratio of 48.15, a PEG ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm posted $3.46 EPS. Equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.90%. Stryker’s dividend payout ratio is 43.30%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. JPMorgan Chase & Co. upped their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Argus set a $450.00 target price on shares of Stryker in a report on Monday, February 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Finally, Truist Financial upped their target price on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $421.90.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.